Chau Dang, MD, Memorial Sloan Kettering Westchester

home / authors / chau-dang-md-memorial-sloan-kettering-westchester

Articles

Chau T. Dang, MD

Dr. Dang on the Design of the BERENICE Trial in HER2+ Breast Cancer

Chau Dang, MD, Memorial Sloan Kettering Westchester
September 16th 2021

Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.

Read More

Q&A: Practical Considerations in HER2+ Breast Cancer

Q&A: Practical Considerations in HER2+ Breast Cancer

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

The Impact of Subcutaneous Option for HER2+ BC

The Impact of Subcutaneous Option for HER2+ BC

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Clinical Outcomes in HER2+ BC: FeDeriCa and PHranceSCa

Clinical Outcomes in HER2+ BC: FeDeriCa and PHranceSCa

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BC

Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BC

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Administration of Dual HER2-Targeted Therapy in BC

Administration of Dual HER2-Targeted Therapy in BC

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Dual HER2-Targeted Approaches in Breast Cancer

Dual HER2-Targeted Approaches in Breast Cancer

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Historic Perspectives on HER2+ Breast Cancer

Historic Perspectives on HER2+ Breast Cancer

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Latest Updated Articles

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Reid Merryman, MD
Published: September 5th 2024 | Updated: September 10th 2024
Dr Merryman on the Evolution of MRD Assays in Lymphoma
Published: April 17th 2024 | Updated: September 10th 2024
The Impact of CAR T Cell Therapy on Managing R/R LBCL